Literature DB >> 22999188

Antibodies against Wnt receptor of muscle-specific tyrosine kinase in myasthenia gravis.

Masaharu Takamori1, Tatsufumi Nakamura, Masakatsu Motomura.   

Abstract

Muscle-specific tyrosine kinase (MuSK) antibodies are detected in a proportion of myasthenia gravis (MG) patients who are negative for acetylcholine receptor (AChR) antibodies and have prominent bulbar weakness and crises. In the MuSK ectodomains, the immunoglobulin-like 1 and 2 domains (Ig1/2) mediate the agrin-Lrp4-MuSK signaling and the cysteine-rich domain (CRD) mediates the Wnt-MuSK-Dishevelled signaling; both contribute to AChR clustering. Immunoblotting against recombinant proteins showed MuSK Ig1/2 antibodies in 33 anti-AChR-negative MG patients; 10 patients of them (30%) were additionally positive for MuSK CRD antibodies. The result suggests that MuSK antibodies have heterogeneity in their binding to functional domains of MuSK.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999188     DOI: 10.1016/j.jneuroim.2012.09.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Authors:  Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

2.  Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.

Authors:  Kenji Otsuka; Mikako Ito; Bisei Ohkawara; Akio Masuda; Yu Kawakami; Ko Sahashi; Hiroshi Nishida; Naoki Mabuchi; Akemi Takano; Andrew G Engel; Kinji Ohno
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

Review 3.  Synaptic Homeostasis and Its Immunological Disturbance in Neuromuscular Junction Disorders.

Authors:  Masaharu Takamori
Journal:  Int J Mol Sci       Date:  2017-04-24       Impact factor: 5.923

Review 4.  Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Lucia S Borges; David P Richman
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

5.  MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.

Authors:  Maartje G Huijbers; Dana L Vergoossen; Yvonne E Fillié-Grijpma; Inge E van Es; Marvyn T Koning; Linda M Slot; Hendrik Veelken; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-02-21

Review 6.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

Review 7.  The Muscle Is Not a Passive Target in Myasthenia Gravis.

Authors:  Jean-Thomas Vilquin; Alexandra Clarissa Bayer; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Neurol       Date:  2019-12-19       Impact factor: 4.003

8.  MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.

Authors:  Inga Koneczny; Judith Cossins; Patrick Waters; David Beeson; Angela Vincent
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

Review 9.  Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system.

Authors:  Nese Sinmaz; Tina Nguyen; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  J Neuroinflammation       Date:  2016-08-30       Impact factor: 8.322

10.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.